Sentinel Oncology Limited announce first dose in phase 1 cancer trial for SOL578
Cambridge, UK, August 28, 2023 – Sentinel Oncology Limited today announced that its partner, PharmaEngine Inc (TWO: 4162) has initiated a phase 1 trial for haemtological cancers with SOL578.
Sentinel Oncology Limited entered into an exclusive license agreement with Taiwan based pharmaceutical company PharmaEngine, Inc. (TWO: 4162) in September 2022 to advance the development of SOL578. Under the terms of the agreement, Sentinel is eligible to receive regulatory and sales milestones in addition to royalties from net product sales of SOL578.
About Sentinel Oncology Limited
Sentinel Oncology was founded in 2005 in Cambridge, UK and is a fully integrated drug discovery company developing and commercializing high quality drug candidates for cancer and other diseases where there is currently an unmet medical need. Our pipeline is focused on the design and optimisation of new drugs which can be used to treat primary brain tumours or systemic tumours which frequently metastasise to the brain. Find out more by visiting Sentinel Oncology’s website at
https://www.sentineloncology.com.
About PharmaEngine (TWO: 4162)
PharmaEngine, Inc., headquartered in Taipei, was established in February 2003. PharmaEngine focuses on new drug development by adopting “Virtual Pharmaceutical Company Business Model”. PharmaEngine has one commercial product, ONIVYDE®, which has received marketing approvals in more than 40 countries worldwide for the treatment of metastatic pancreatic cancer patients who have progressed on gemcitabine. PharmaEngine is current advancing and growing early-stage pipelines. For further information, please visit PharmaEngine’s website at
